Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Weight-Loss surgery alter how medications work?

NCT ID NCT07748273

Knowledge-focused Sponsor: Hospital das Clínicas de Ribeirão Preto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study looks at how two common medications, rosuvastatin (a cholesterol drug) and losartan (a blood pressure drug), are absorbed in people who have had weight-loss surgery. Sixty adults scheduled for either Roux-en-Y gastric bypass or sleeve gastrectomy will take a single dose of each drug before and about 12 weeks after surgery. Researchers will measure drug levels in the blood to see if surgery changes how much of the drug gets into the body, and they will also examine stool samples to explore whether gut bacteria play a role.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rosuvastatin and losartan, given as single oral doses before and after bariatric surgery
What this could lead to
If successful, this could help doctors adjust medication doses for people after weight-loss surgery, improving treatment safety and effectiveness.
What could go wrong
This is a small, early-stage study with only 60 participants, so results may not apply to everyone. It measures drug levels, not health outcomes, and the findings may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 65 years; * Formal clinical indication for RYGB or sleeve gastrectomy after multidisciplinary assessment; * Bariatric surgery scheduled and no previous bariatric procedure; * Able to understand the study and provide written informed consent. Exclusion Criteria: * Moderate or severe hepatic impairment, liver enzymes greater than 3 times the upper limit of normal, or Child-Pugh class B or C. * Estimated glomerular filtration rate below 30 mL/min/1.73 m². * Concomitant use of drugs that substantially affect rosuvastatin pharmacokinetics and cannot be temporarily discontinued, including cyclosporine, gemfibrozil, or potent OATP1B1/BCRP or CYP2C9 inhibitors. * Systemic antibiotic use within 3 months or probiotic, prebiotic, or synbiotic use within 4 weeks before sampling. * Continuous current rosuvastatin or other statin therapy unless medically discontinued with an adequate washout period under physician supervision. * Clinically relevant baseline hypotension, significant hyperkalemia, renal impairment, or another condition that makes a losartan test dose unsafe. * Severe postoperative complication preventing oral dosing, including active gastrointestinal leak, intractable vomiting, or severe anastomotic stenosis. * Pregnancy. Participants of childbearing potential undergo routine preoperative beta-hCG testing.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bariatric surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bariatric surgery Drug absorption Obesity & overweight Pharmacokinetics after oral intake

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital das Clínicas, Ribeirão Preto Medical School, University of São Paulo

    Ribeirão Preto, São Paulo, 14048900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.